Get the Stockscreener App
15.14
7.38%
+1.04
Gyre Therapeutics Inc stock is currently priced at $15.14, with a 24-hour trading volume of 36,533.
It has seen a +7.38% increased in the last 24 hours and a -11.77% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $14.54 pivot point. If it approaches the $15.28 resistance level, significant changes may occur.
Previous Close:
$14.10
Open:
$14
24h Volume:
36,533
Market Cap:
$1.29B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-11.51%
1M Performance:
-11.77%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1D Range:
$14.00
$15.15
52W Range:
$10.41
$27.10
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Name
Gyre Therapeutics Inc
Sector
Industry
Phone
650-871-0761
Address
611 GATEWAY BLVD., SUITE 710, SOUTH SAN FRANCISCO
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
View All
Gyre Therapeutics Inc Stock (GYRE) Latest News
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
Benzinga
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire Inc.
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
GlobeNewswire Inc.
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Gyre Therapeutics Inc Stock (GYRE) Financials Data
There is no financial data for Gyre Therapeutics Inc (GYRE). Check out other stocks for more information.
About Gyre Therapeutics Inc
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
1.62%
0.15%
Cap:
|
Volume (24h):